A recent Ozempic and Wegovy NAION study made two new findings about people who used Ozempic or Wegovy and then were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) as a drug side effect that caused vision loss. The first is that the Wegovy NAION rate is five times that of Ozempic. The second is that for users of Ozempic and Wegovy, NAION was diagnosed in men three times more than in women.
These findings from the Ozempic and Wegovy NAION study were presented in this March 2026 British Journal of Ophthalmology article, “Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk“.
News Articles About
Ozempic and Wegovy NAION Study
Here are three news articles that provide the details and some contextual information about the Ozempic and Wegovy NAION study 2026 report:
“Wegovy May Carry Highest Risk of Blinding Condition Among GLP-1 Drugs“, MedPage Today, 3/10/26
“Wegovy linked to higher risk of eye stroke and vision loss“, BMJ Group, 3/10/26
“Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds“, The Guardian, 3/10/26
We have been following the vision side-effect drug safety issue that is the subject of this Ozempic and Wegovy NAION study report since July 2024. During that time, we have investigated possible drug injury lawsuits against Novo Nordisk for patients diagnosed with NAION and who suffered vision loss.
Earlier Posts Related to
Ozempic and Wegovy NAION Study
Related to this Ozempic and Wegovy NAION study 2026 report, here is a list of some of our earlier posts about non-arteritic anterior ischemic optic neuropathy (NAION) associated with the semaglutide-containing drugs Wegovy and Ozempic, as well as Rybelsus, all from Novo Nordisk:
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
If you have a possible NAION drug injury lawsuit involving one of the semaglutide drugs from Novo Nordisk that you want reviewed, you can can submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online, send an email to TJL@LambLawOffice.com, or call us at 910-256-2971.
[Read the article in full at Drug Injury Watch]Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation